[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537002":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":44,"locations":54,"responsibleParty":110,"collaborators":113,"id":123,"slug":124,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":125,"sex":131,"minAge":132,"maxAge":18,"enrollmentInfo":133,"targetDuration":18,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":144,"whyStopped":18,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"UMC Utrecht","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention arm","EXPERIMENTAL","Patients in the intervention arm will receive locally ablative stereotactic MRgRT in addition to standard of care, consisting of 5 times 10 Gy MR guided radiotherapy.",[13],"Radiation: MR guided radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","Patients randomized to the control arm will continue standard of care as described without additional local treatment.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"RADIATION","MR guided radiotherapy","5 fractions of 10 Gray MRgRT in addition to standard of care",[9],[26,30,32,35,38,41],{"name":27,"affiliation":28,"role":29},"L. A. Daamen, MD, PhD","Regional Academic Cancer Center Utrecht (RACU)","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":28,"role":29},"M P.W. Intven, MD, PhD",{"name":33,"affiliation":34,"role":29},"A. M.E. Bruynzeel, MD, PhD","Amsterdam University Medical Center, VUmc",{"name":36,"affiliation":37,"role":29},"H. D. Heerkens, MD, PhD","Radboud University Medical Center",{"name":39,"affiliation":40,"role":29},"H. M.U. Peulen, MD, PhD","Catharina Ziekenhuis Eindhoven",{"name":42,"affiliation":43,"role":29},"J. J. Bosch","Centre of Human Drug Research",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":18,"email":49},"Lois Daamen, MD, PhD","CONTACT","+ 316 51223276","L.a.daamen-3@umcutrecht.nl",{"name":51,"role":47,"phone":52,"phoneExt":18,"email":53},"Jacobien Scheepens, MD","+31 6 21477044","j.c.m.scheepens-7@umcutrecht.nl",[55,72,84,95],{"facility":56,"status":18,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Catharina Hospital","Eindhoven","North Brabant","5623 EJ","Netherlands","NL",{"type":63,"coordinates":64},"Point",[65,66],5.47778,51.44083,{"lat":66,"lon":65},[69,71],{"name":70,"role":47,"phone":18,"phoneExt":18,"email":53},"J. C.M. Scheepens, MD",{"name":39,"role":29,"phone":18,"phoneExt":18,"email":18},{"facility":34,"status":18,"city":73,"state":74,"zip":75,"country":60,"countryCode":61,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Amsterdam","North Holland","1081 HV",{"type":63,"coordinates":77},[78,79],4.88969,52.37403,{"lat":79,"lon":78},[82,83],{"name":70,"role":47,"phone":18,"phoneExt":18,"email":53},{"name":33,"role":29,"phone":18,"phoneExt":18,"email":18},{"facility":37,"status":18,"city":85,"state":18,"zip":86,"country":60,"countryCode":61,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Nijmegen","6525 GA",{"type":63,"coordinates":88},[89,90],5.85278,51.8425,{"lat":90,"lon":89},[93,94],{"name":70,"role":47,"phone":18,"phoneExt":18,"email":53},{"name":36,"role":29,"phone":18,"phoneExt":18,"email":18},{"facility":96,"status":18,"city":97,"state":18,"zip":98,"country":60,"countryCode":61,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"University Medical Center Utrecht","Utrecht","3584CX",{"type":63,"coordinates":100},[101,102],5.12222,52.09083,{"lat":102,"lon":101},[105,106,107],{"name":70,"role":47,"phone":18,"phoneExt":18,"email":53},{"name":27,"role":29,"phone":18,"phoneExt":18,"email":18},{"name":108,"role":109,"phone":18,"phoneExt":18,"email":18},"M. P.W. Intven, MD, PhD","SUB_INVESTIGATOR",{"type":29,"investigatorFullName":111,"investigatorTitle":112,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Lois Daamen","Prinipal Investigator",[114,116,117,118,120],{"name":115,"class":6},"Amsterdam UMC, location VUmc",{"name":37,"class":6},{"name":40,"class":6},{"name":119,"class":6},"Centre for Human Drug Research, Netherlands",{"name":121,"class":122},"Dutch Pancreatic Cancer Group (DPCG)","UNKNOWN","100537002","locally-advanced-pancreatic-cancer-after-systemic-therapy-ablative-mr-guided-radiotherapy-100537002",false,"NCT06272162","Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy","Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy, a Randomized Controlled Trial","LAPSTAR","Inclusion Criteria:\n\n* Pathology proven pancreatic ductal adenocarcinoma (PDAC);\n* At least two (preferably four) months systemic therapy with (m)FOLFIRINOX and\u002For gemcitabine + nab-paclitaxel; or eligibility for chemotherapy but no initiation of chemotherapy based on patients' wish;\n* No option for surgical resection, either because anatomical irresectability based on the surgeon's judgement (assessed on imaging or during explorative laparotomy) and\u002For frailty (unfit for surgery or chemotherapy) and\u002For no surgery based on patient's wish.\n* No evidence of distant metastatic disease progression, evaluated by CT Thorax \u002F Abdomen \u002F Pelvis and\u002For PET-CT scan;\n* Performance status WHO 0-2.\n\nExclusion Criteria:\n\n* Contra-indications for MRI or CT with an intravenous contrast agent according to the protocol of the local radiology and\u002For radiotherapy departments\n\n  * Contraindications for MRgRT, as determined by the involved expert radiation oncologists of the Consortium\n  * \\\u003C18 years old\n  * Pregnancy","ALL","18 Years",{"count":134,"type":135},150,"ESTIMATED","INTERVENTIONAL",[138],"NA","A randomized controlled trial comparing the effect of local ablative MR-guided radiotherapy (MRgRT) after systemic therapy with current standard treatment alone, on health-related quality of life in patients with locally advanced pancreatic cancer (LAPC).",[141],"Locally Advanced Pancreatic Adenocarcinoma",[143],"MR guided radiation therapy","NOT_YET_RECRUITING","2024-02-14",{"date":147,"type":148},"2024-02-22","ACTUAL",{"date":150,"type":135},"2024-02",{"date":152,"type":135},"2030-01",{"name":5,"class":6},4]